adenomyosis
Conditions
Interventions
A:HIFU
B:a long period Half GnRha
C:HIFU + a long period Half GnRHa
Sponsors
Anhui Provincial Cancer Hospital
Eligibility
Sex/Gender
Female
Age
25 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1. Premenopausal women aged between 25 to 50 years; 2. Confirmed adenomyosis by history, examination,CA125, MRI or ultrasound; 3. maxium diameter of adenomyoma is more than 3cm; 4. Receive no other steroid hormone medications within 3 months; 5. Be voluntory to this trial and sign the consent form. ;Inclusion criteria: 1. Premenopausal women aged between 25 to 50 years; 2. Confirmed adenomyosis by history, examination,CA125, MRI or ultrasound; 3. maxium diameter of adenomyoma is more than 3cm; 4. Receive no other steroid hormone medications within 3 months; 5. Be voluntory to this trial and sign the consent form. ;Inclusion criteria: 1. Premenopausal women aged between 25 to 50 years; 2. Confirmed adenomyosis by history, examination,CA125, MRI or ultrasound; 3. maxium diameter of adenomyoma is more than 3cm; 4. Receive no other steroid hormone medications within 3 months; 5. Be voluntory to this trial and sign the consent form. ;Inclusion criteria: 1. Premenopausal women aged between 25 to 50 years; 2. Confirmed adenomyosis by history, examination,CA125, MRI or ultrasound; 3. maxium diameter of adenomyoma is more than 3cm; 4. Receive no other steroid hormone medications within 3 months; 5. Be voluntory to this trial and sign the consent form. ;Inclusion criteria: 1. Premenopausal women aged between 25 to 50 years; 2. Confirmed adenomyosis by history, examination,CA125, MRI or ultrasound; 3. maxium diameter of adenomyoma is more than 3cm; 4. Receive no other steroid hormone medications within 3 months; 5. Be voluntory to this trial and sign the consent form.
Exclusion criteria
Exclusion criteria: 1. Maxium diameter of Uterine is more than 10cm, suspicious malignant transformation; 2. Be allergic to or contraindicated to HIFU, GnRH-a; 3. Be pregnant, with accute genital tract inflamation or gynecological malignant diseases such as ovarian cancer; 4. Receive other steroid hormone medications within 3 months. ;Exclusion criteria: 1. Maxium diameter of Uterine is more than 10cm, suspicious malignant transformation; 2. Be allergic to or contraindicated to HIFU, GnRH-a; 3. Be pregnant, with accute genital tract inflamation or gynecological malignant diseases such as ovarian cancer; 4. Receive other steroid hormone medications within 3 months. ;Exclusion criteria: 1. Maxium diameter of Uterine is more than 10cm, suspicious malignant transformation; 2. Be allergic to or contraindicated to HIFU, GnRH-a; 3. Be pregnant, with accute genital tract inflamation or gynecological malignant diseases such as ovarian cancer; 4. Receive other steroid hormone medications within 3 months. ;Exclusion criteria: 1. Maxium diameter of Uterine is more than 10cm, suspicious malignant transformation; 2. Be allergic to or contraindicated to HIFU, GnRH-a; 3. Be pregnant, with accute genital tract inflamation or gynecological malignant diseases such as ovarian cancer; 4. Receive other steroid hormone medications within 3 months. ;Exclusion criteria: 1. Maxium diameter of Uterine is more than 10cm, suspicious malignant transformation; 2. Be allergic to or contraindicated to HIFU, GnRH-a; 3. Be pregnant, with accute genital tract inflamation or gynecological malignant diseases such as ovarian cancer; 4. Receive other steroid hormone medications within 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| dysmenorrhea symptoms;Dysmenorrhea degree;Lesion reduction rate;Menstrual volume;Uterine volume reduction rate;Ablation rate; | — |
Countries
China
Contacts
Public ContactZhao Weidong;Zhao Weidong;Zhao Weidong;Zhao Weidong;Zhao Weidong ;;;;
Anhui Provincial Cancer Hospital;Anhui Provincial Cancer Hospital;Anhui Provincial Cancer Hospital;Anhui Provincial Cancer Hospital;Anhui Provincial Cancer Hospital
Outcome results
None listed